Despite advancements in antithrombotic therapies, patients with acute coronary syndrome (ACS) continue to face high rates of recurrent ischemic events, particularly in the early phase following hospitalization. Many patients are not optimally protected due to limitations of current therapies.
J&J’s approach to acute coronary syndrome
Through the Librexia ACS trial, Johnson & Johnson, in collaboration with Bristol Myers Squibb, is evaluating an investigational FXIa inhibitor, for its potential to offer effective protection against thrombotic events without increasing bleeding risk. This trial is part of our broader commitment to transform care for patients with complex cardiovascular conditions.
By exploring a novel mechanism, Factor XIa inhibition, we hope to address persistent gaps in secondary prevention and help more patients access treatment.
We are determined to close the gap in unmet needs in thrombosis management by overcoming the limits of today’s treatments.
